| Line Item | 2025-12-31 | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $10.0M | — | — |
| R&D Expense | $315K | — | — |
| SG&A Expense | $4.7M | — | +3155.6% |
| Operating Income | -$6.6M | — | -3123.8% |
| Interest Expense | $143K | — | — |
| Pre-tax Income | -$6.9M | — | -3304.6% |
| Net Income | -$6.9M | — | -3304.6% |
| Line Item | 2025-12-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $16K | — | — |
| Current Assets | $4.0M | +48.6% | — |
| Total Assets | $18.4M | +582.1% | +388.2% |
| Current Liabilities | $15.3M | +5.7% | +182.2% |
| Total Liabilities | $15.3M | +5.7% | +170.4% |
| Stockholders' Equity | $3.1M | +126.0% |
| Line Item | 2025-12-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$5.4M | — | -5087.4% |
| Investing Cash Flow | -$329K | — | — |
| Financing Cash Flow | $6.1M | — | — |
| +151.2% |